These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1622160)

  • 21. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of an orally administered cephalosporin, LY164846, against potentially pathogenic respiratory and dermal bacterial isolates.
    Lauderdale BL; Yu PK; Washington JA
    Antimicrob Agents Chemother; 1986 Apr; 29(4):560-4. PubMed ID: 3486628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma bactericidal activity of a new C-5 methyl fluoroquinolone after oral doses of 400 and 800 mg.
    Gu JW; Fang W; Neu HC
    J Clin Pharmacol; 1992 Sep; 32(9):804-7. PubMed ID: 1331205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol.
    Carsenti-Etesse H; Farinotti R; Durant J; Roger PM; De Salvador F; Bernard E; Rouveix B; Dellamonica P
    Eur J Drug Metab Pharmacokinet; 1998; 23(3):357-66. PubMed ID: 9842977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative kill and growth rates determined with cefdinir and cefaclor and with Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Antimicrob Agents Chemother; 1992 Jan; 36(1):46-9. PubMed ID: 1590698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro, in-vivo and ex-vivo studies with oral beta-lactams against Streptococcus pneumoniae.
    Pérez-Trallero E; Alkorta M; García-Arenzana JM; Iturzaeta A; Gomariz M
    J Antimicrob Chemother; 1998 Jun; 41(6):629-34. PubMed ID: 9687101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
    Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
    Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro susceptibility of Haemophilus influenzae to loracarbef (LY 163892) and other oral antibiotics. Collaborative Study Group on Pediatric Infectious Disease in Lombardy.
    Garlaschi ML; Colombo R; Varotto F; Conio F; Rusconi F; Sideri S; Gagliardi L; Sala A; Arghittu M
    J Chemother; 1991 Jan; 3 Suppl 1():47-50. PubMed ID: 12043716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.
    Paulfeuerborn W; Müller HJ; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1835-41. PubMed ID: 8239592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
    Dan M; Poch F; Edelman A; Asherov J; Hafely H; Atzmon Y
    J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
    Hyatt JM; Nix DE; Schentag JJ
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2730-7. PubMed ID: 7695254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bactericidal activity and postantibiotic effect of cefdinir (Cl 983, FK 482) against selected pathogens.
    Blandino G; Caccamo F; Di Marco R; Nicoletti A; Speciale A; Nicoletti G
    Drugs Exp Clin Res; 1992; 18(8):319-27. PubMed ID: 1292914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens.
    Speciale A; Caccamo F; Blandino G; Giacchi GT; Aleo G; Nicoletti G
    Chemotherapy; 1996; 42(1):1-10. PubMed ID: 8751262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma bactericidal activity after administration of erythromycin estolate and erythromycin ethylsuccinate to healthy volunteers.
    Bérubé D; Kirouac D; Croteau D; Bergeron MG; Lebel M
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1227-30. PubMed ID: 3142349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of BAY v 3522, a new oral cephalosporin.
    Fass RJ
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1855-7. PubMed ID: 2126697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.